Genasense

M.D. Anderson Cancer Center · discontinued Small molecule

Genasense is a Small molecule drug developed by M.D. Anderson Cancer Center. It is currently in discontinued development. Also known as: G3139, Oblimersen.

Genasense, also known as oblimersen sodium, is an antisense oligonucleotide that targets Bcl-2 mRNA. It is being studied as a potential treatment for various types of cancer, including Diffuse Large Cell Lymphoma and Lung Cancer.

At a glance

Generic name	Genasense
Also known as	G3139, Oblimersen
Sponsor	M.D. Anderson Cancer Center
Modality	Small molecule
Therapeutic area	Other
Phase	discontinued

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Phase I Study of Antisense Bcl-2 Oligonucleotide (G3139) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors (Phase 1)
• Phase I/II Study of G3139 (Genasense) in Patients With Waldenstrom's Macroglobulinemia (Phase 1)
• Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia (Phase 3)
• A Phase I/II Study of G3139, a BCL-2 Antisense Oligonucleotide, Combined With Paclitaxel for the Treatment of Recurrent Small Cell Lung Cancer (Phase 1)
• Continuation Protocol For G3139 (Bcl-2 Antisense Oligonucleotide) And Dacarbazine In Patients With Malignant Melanoma Who Responded To This Combination In Protocol GM301 (NA)
• A Pharmacokinetic and Safety Assessment of G3139 Administered by Subcutaneous Injection to Patients With Solid Tumors (Phase 1)
• A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas (Phase 2)
• Investigator Initiated Pilot Study of Microarray Directed Therapy for Diffuse Large B-cell Lymphoma Using Genasense With CHOP-R (EARLY/Phase 1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Genasense CI brief — competitive landscape report
• Genasense updates RSS · CI watch RSS
• M.D. Anderson Cancer Center portfolio CI

Frequently asked questions about Genasense

What is Genasense?

Genasense is a Small molecule drug developed by M.D. Anderson Cancer Center.

Who makes Genasense?

Genasense is developed by M.D. Anderson Cancer Center (see full M.D. Anderson Cancer Center pipeline at /company/m-d-anderson-cancer-center).

Is Genasense also known as anything else?

Genasense is also known as G3139, Oblimersen.

What development phase is Genasense in?

Genasense is in discontinued.

Related

• Manufacturer: M.D. Anderson Cancer Center — full pipeline
• Therapeutic area: All drugs in Other
• Also known as: G3139, Oblimersen